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T Cells Distinguish MHC-Peptide Complexes
Formed in Separate Vesicles and Edited by H2-DM
Dessen et al., 1997; Scott et al., 1998; Fremont et al.,
1998a; Corper et al., 2000; Latek et al., 2000a). The few
class II MHC-peptide-TCR structures resolved thus far
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support this model, with the TCR contacting the MHC-Washington University School of Medicine
peptide complex at an orthogonal angle and interactingSt. Louis, Missouri 63110
with the peptide core and MHC helices (Reinherz et al.,2 Department of Molecular and Cellular Biology
1999; Hennecke et al., 2000; Hennecke and Wiley, 2002).Harvard University
It has become clear, however, that this paradigm isCambridge, Massachusetts 02138
incomplete. Residues outside the core can contribute
both to binding (Nelson et al., 1994; Anderson and Gor-
ski, 2003) and to T cell recognition (Carson et al., 1997;Summary
Arnold et al., 2002), and class II MHC-peptide complexes
can form in compartments other than those of the ca-The peptide spanning residues 48–61 of hen egg white
nonical pathway of antigen processing, including in earlylysozyme (HEL) presented by I-Ak gives rise to two
endosomes and at the cell surface (Lindner and Unanue,T cell populations, referred to as type A and B, that
1996; Griffin et al., 1997; Pinet and Long, 1998). Further-distinguish the complex generated intracellularly upon
more, it has been demonstrated that the same peptideprocessing of HEL from that formed with exogenous
and MHC molecule can complex in multiple forms, andpeptide. Here, we ascribe this difference to recogni-
that T cells can discriminate between them. Our labora-tion of distinct conformers of the complex and show
tory described such a phenomenon when identifyingthat formation of the two complexes results from an-
epitopes of hen egg white lysozyme (HEL) presented bytigen processing in different intracellular compart-
I-Ak and I-Ek (Viner et al., 1995, 1996; see below). Jane-ments and is dependent upon H2-DM. While the type
way and colleagues described multiple forms of anA complex preferentially formed in a lysosome-like
MHC-peptide complex formed by E52-68 and I-Ab, whichlate vesicle, the type B complex failed to form in this
varied in their ability to be negatively selected in micecompartment; this distinction was abolished in anti-
that express E (Barlow et al., 1998; Chervonsky et al.,gen-presenting cells lacking DM. Experiments in vitro
1998; Viret et al., 2001, 2003). Similarly, studies of experi-indicated that H2-DM acts directly on the complex to
mental autoimmune encephalitis induced by immuniza-eliminate the type B conformation. We conclude that
tion with the acetylated 1–11 peptide of myelin basicdifferent antigen-processing pathways generate dis-
protein (MPB) indicated that this peptide complexestinct MHC-peptide conformers, priming T cells with
with I-Au in multiple states and that specific recognitiondistinct specificity that may play unique roles in im-
of an “aberrant” complex may be a critical pathogenicmunity.
mechanism in this disease model (He et al., 2002; Huang
et al., 2003). Divergent T cell recognition of multiple
forms of the same MHC-peptide complex likely explainsIntroduction
several long-standing observations in immunology, from
the immunogenicity of derivatized self-proteins (Land-Recognition of class II MHC-peptide complexes by
steiner, 1945) to the failure of “cryptic” epitopes to elicitCD4 T lymphocytes is the central event of adaptive
T cell responses (Sercarz et al., 1993; Peterson et al.,immunity, required for full initiation of both the humoral
1999). However, the structural differences between
and the cellular response. Conventionally, these com-
these complexes and, more importantly, the biological
plexes are generated by the interaction of peptides,
mechanisms which govern their formation remain
generated through processing of internalized proteins, largely unknown.
with MHC molecules in late endocytic vesicles of anti- We have investigated this issue of multiple forms of
gen-presenting cells (reviewed in Cresswell, 1994; Hud- a peptide-MHC complex through our studies of HEL
son and Ploegh, 2002; Unanue, 2002). The nature of this and its presentation by I-Ak. CD4 T cells primed by
interaction has been elucidated by biochemical analysis immunization with the dominant peptide processed
of processed peptides and, more recently, by structural from HEL, spanning residues 48–63, segregate into two
resolution of class II MHC-peptide complexes. Peptides subsets. For most T cells, the complex formed in APC
consist of a core of nine residues which occupy the with exogenous peptide recapitulates that formed by
peptide binding groove and flanks of varying length that the processing of native protein (type A). However, a
extend outside the groove; within the core, the side significant number (in excess of 30%) recognize the
chains of residues P1, P4, P6, and P9 occupy pockets complex formed by peptide offered exogenously to
in the groove and determine the stability and specificity APC, but not the complex formed by the identical pep-
of binding, while the side chains of residues P2, P5, and tide derived from intracellular processing (type B) (Viner
P8 extend upward from the groove and contact the TCR et al., 1995, 1996; Peterson et al., 1999; Pu et al., 2002).
(Allen et al., 1987; Sette et al., 1987, Stern et al., 1994; The potential importance of this phenomenon was high-
lighted by the observation that type B T cells escape
thymic negative selection and peripheralize under con-*Correspondence: unanue@pathbox.wustl.edu
3These authors contributed equally to this work. ditions in which type A T cells to the same epitope
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underwent complete thymic central deletion; this was reasoned that analogous to its peptide-editing function,
found with type B T cells reactive to the 48–62 epitope DM might favor formation of stable forms of the MHC-
of HEL in mice transgenic for HEL expression (Peterson peptide complex, i.e., type A versus type B.
et al., 1999), as well as with type B T cells recognizing a Here, we have investigated the mechanism of selec-
highly abundant autologous epitope in wild-type B10.BR tive generation of type A and B complexes using a com-
mice (Lovitch et al., 2003a). The latter finding indicated bination of biochemical and cellular approaches. We
that self-reactive type B T cells are present in the naive demonstrate that the type A and B conformers form
repertoire, where their activation can result in autoim- in distinct vesicles, with the type A conformer forming
mune pathology. preferentially in late endosomal/lysosomal vesicles and
A substantial body of evidence supports the hypothe- the type B conformer restricted to the early endosome
sis that type A and B T cells recognize alternate con- and cell surface, and that this restriction is mediated
formational isomers (conformers) of the same MHC- through the action of DM. We also show that DM acts
peptide complex. Type B reactivity is not explained by directly on the MHC-peptide complex to abolish the type
failure of the APC to generate the peptide during pro- B conformer, thus behaving as a conformational editor
cessing, as mass spectrometric analysis of MHC-bound of MHC-peptide complexes.
peptides identified the peptide in high abundance (Viner
et al., 1995, 1996; Lovitch et al., 2003a). It is not the Results
result of postsynthetic (Peterson et al., 1999; Lovitch
et al., 2003a) or posttranslational modification of the Type A and B Complexes Form in Distinct
peptide (Cirrito et al., 2001), or of peptide binding in an Intracellular Compartments
alternate register (Nelson et al., 1996; Pu et al., 2002); To evaluate whether the intracellular compartment in
these phenomena have been observed in other systems which MHC and peptide interact might explain the dis-
but fail to explain our findings. While native HEL stimu- tinction between the A and B states of the I-Ak/48–61
lated only the type A T cell subset, chemically denatured complex, we used liposomes to selectively deliver anti-
HEL stimulated both subsets. Furthermore, the complex gen to these vesicles. Liposomes composed of dioleoyl-
of 48–61 and I-Ak formed in vitro by peptide exchange phosphatidylcholine and dioleoylphosphatidylserine
was recognized by both type A and B T cells; however, (DOPC/DOPS) are highly pH stable; upon phagocytosis,
when the peptide was covalently linked to I-Ak, the re- they transit through the endocytic pathway, ultimately
sulting complex was only recognized by type A T cells releasing their contents in a late vesicle with lysosomal
(Peterson et al., 1999). Finally, analysis of type A and B properties due to enzymatic degradation of the liposome
T cells indicated distinct patterns of T cell receptor- bilayer. In contrast, dioleoylphosphatidylethanolamine/
contact residue usage by the two subsets (Pu et al., cholesteryl hemisuccinate (DOPE/CHEMS) liposomes
2002). are rendered acid labile by the presence of an ionizable
Given the disparate responses of type A and B T cells succinate moiety in the bilayer; as a result, they release
to protein and exogenous peptide, we hypothesized that their contents upon reduction of the pH below 6.5,
formation of MHC-peptide complexes in distinct intra-
which occurs in the early endosome (Connor et al.,
cellular compartments might underlie the generation of
1984.; Harding et al., 1991; Collins et al., 1992).
the two conformers. Loading of exogenous peptide and
We encapsulated 48–63 peptide in DOPC/DOPS lipo-
processing of native protein occur by distinct pathways;
somes (for lysosomal delivery) and DOPE/CHEMS lipo-
unfolded proteins and peptides complex with class II
somes (for endosomal delivery), then offered both formsMHC molecules in an early endocytic compartment,
of liposomal peptide, as well as free peptide, to perito-while processing of HEL requires a late compartment
neal macrophages, and tested presentation to type Athat contains nascent class II molecules and reductive
and B hybridomas. Type A hybridomas responded toactivity (Rudensky et al., 1994; Lindner and Unanue,
both forms of liposomal peptide, as well as to free pep-1996; Arunachalam et al., 2000). Furthermore, we hy-
tide. Notably, however, the dose of lysosome-targetedpothesized that H2-DM (HLA-DM in humans, abbrevi-
peptide required to induce a type A response was farated DM), an important accessory molecule in the class
lower than that for endosome-targeted or free peptide,II processing pathway (reviewed by Busch et al., 2000),
indicating preferential formation of the type A complexmight play a role in the mechanism. Synthesis of HLA-
in the lysosome (Figures 1A and 1B). This observationDR in the absence of DM affects its recognition by mono-
could not be explained by different rates of uptake ofclonal antibodies, suggesting alteration of either peptide
the liposomal formulations, as the rate of uptake DOPE/content or of conformation (Fling et al., 1994, 1997; Ver-
CHEMS liposomes by peritoneal macrophages was 3- toreck et al., 2001), and DM is thought to alter the confor-
4-fold greater than that for DOPC/DOPS liposomesmation of the binding groove (Chou and Sadegh-Nas-
(Harding et al., 1991). In stark contrast, type B hybrido-seri, 2000; Pashine et al., 2003). DM acts as a chaperone
mas responded poorly to lysosome-targeted peptide,during synthesis of class II MHC, preventing aggregation
but responded well to endosome-targeted peptide andand degradation in the ER (Denzin et al., 1996; Krop-
to free peptide, which loads in the early endosome andshofer et al., 1997) in a manner analogous to that de-
at the cell surface (Figures 1C and 1D). We obtainedscribed for invariant chain (Bonnerot et al., 1994;
similar results with primary dendritic cells, although theCastellino and Germain, 1995; Romagnoli and Germain,
responses of the hybridomas were considerably weaker1995; Zhong et al., 1997). Most critically, DM “edits” the
due to the reduced phagocytic capacity of these cellsrepertoire of peptides bound to class II MHC, favoring
(data not shown).binding of high-affinity epitopes (Sloan et al., 1995; Krop-
Thus, peptide encountering class II MHC in the earlyshofer et al., 1996; van Ham et al., 1996; Weber et al.,
1996; Vogt et al., 1996; Lovitch et al., 2003b). We thus endosome or at the cell surface generated both the type
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Figure 1. Type A and B Complexes Form in
Distinct Compartments by a DM-Dependent
Mechanism
(A–D) Formation of the type A complex is fa-
vored in lysosome-like late vesicles, while for-
mation of the type B complex can occur in
early endosomal vesicles, but not lysosome-
like late vesicles. Synthetic 48–63 peptide
was encapsulated in DOPC/DOPS or DOPE/
CHEMS liposomes as described in the Exper-
imental Procedures. Peritoneal macrophages
were elicited from B10.BR mice, adhered to
96-well flat-bottom plates, and incubated in
the presence of serial dilutions of liposomal
or free peptide for 2 hr at 37C (concentra-
tions of liposomal peptide were determined
based on the amount of input peptide and
the incorporation efficiency), then fixed, and
washed. The indicated hybridoma (5  104/
well) was then added and incubated over-
night at 37C, after which supernatants were
tested for IL-2 content as measured by CTLL
assay. None of the hybridomas responded to
liposomes lacking peptide (not shown).
(E–H) Compartmental segregation of type A
and B complex formation is abolished in
DM/ antigen-presenting cells. Assay condi-
tions were the same as in (A)–(D), with the
exception that peritoneal macrophages were
derived from DM/ mice.
A and type B complexes, but the encounter in a late al., 1994) and requires lysosomal pH for activity (Ullrich
et al., 1997), we hypothesized that it might be involvedvesicle only generated the type A complex. These results
are consistent with previous observations that exoge- in enforcing the preferential formation of the type A
complex in the lysosome and the failure of the typenous peptide generates both complexes at the plasma
membrane (Pu et al., 2002) and that interaction of pep- B complex to form in this compartment. To test this
hypothesis, we examined presentation of liposomal andtide or denatured protein with class II MHC does not
require newly synthesized class II molecules (Davidson free peptide to type A and B hybridomas by DM-deficient
peritoneal macrophages, elicited from DM/mice bear-et al., 1991; Lindner and Unanue, 1996).
ing the H-2k MHC haplotype (Koonce et al., 2003). Type
A hybridomas responded to peptide encapsulated inCompartmental Segregation of Type A and B
Complex Formation Is DM Dependent both liposomal formulations as well as to free peptide,
as in wild-type cells; however, the preferential formationWe next investigated the molecular mechanisms of the
observed compartmental differences. Since DM is most of the type A complex in the lysosome seen in wild-type
cells was abolished, with all three forms of peptide nowabundant in lysosome-like late vesicles (Sanderson et
Immunity
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stimulating the type A hybridomas at equivalent doses (DM→DM at t 70 hr) resulted in a biphasic pattern
similar to that seen with immediate addition of DM; the(Figures 1E and 1F). Furthermore, type B hybridomas
now responded to lysosome-targeted as well as to en- rate of decay of the unstable component was somewhat
accelerated (t1/2  6 hr; 44% of complexes), while thedosome-targeted and free peptide, indicating that the
type B complex was permitted to form in the lysosome rate of decay of the stable component was virtually
unchanged (t1/2  1088 hr). This indicated that DM wasin the absence of DM (Figures 1G and 1H). Thus, com-
partmental differences in formation of the two com- not required to be present during assembly but, rather,
could exert its effect on preformed MHC-peptide com-plexes are DM dependent.
plexes. (The reason for the accelerated decay with addi-
tion of DM at t  70 hr versus t  0 is unclear; mostDevelopment of an In Vitro System
likely, prolonged incubation at 37C nonspecifically de-to Study DM Function
stabilizes some Ak-peptide complexes, which rapidlyTo further investigate the function of DM in determining
dissociate upon introduction of DM.)formation of the type A versus B complexes, we devel-
On the basis of these kinetic data, and by analogyoped an in vitro system to study DM function using
to previous studies demonstrating the ability of DM tosoluble I-Ak-CLIP and H2-DM molecules, based on the
induce dissociation of low-affinity MHC-peptide com-system developed by Mellins and colleagues for human
plexes, we reasoned that in the absence of DM, I-Ak andHLA-DM (Busch et al., 2002). Leucine zippers were fused
48–61 interact to form a mixture of stable and unstableto the C termini of the I-Ak  and  and H2-DM  chains
complexes, and that DM, whether present during forma-to promote stable interaction of the two molecules, a
tion of the complexes or subsequently introduced tothrombin cleavage site was introduced proximal to the
preformed complexes, acted to eliminate the unstableCLIP peptide to allow its dissociation, and an enteroki-
complexes and favor formation of the most stablenase cleavage site was introduced in the DM  chain
complex.to allow its dissociation from I-Ak (Figure 2A). These
molecules formed productive heterodimers in vitro, as
assessed by sandwich ELISA using antibodies to DM The Type B Conformer Is Kinetically Unstable
Relative to the Type A Conformerand I-Ak (Figure 2B). Interestingly, the Ak-DM hetero-
dimer was observed to dissociate on introduction of a To test whether the stable, DM-resistant and unstable,
DM-sensitive components observed in our kinetic analy-high-affinity peptide (48–61) to the complex (Figure 2B);
while this finding is consistent with previous reports sis might correspond to the type A and B conformers
of the complex, we assessed the ability of complexes(Ullrich et al., 1997; Chou and Sadegh-Nasseri, 2000),
to our knowledge it has not previously been directly formed in vitro to stimulate hybridomas of either type
after varying incubation times. Stimulation of type Aobserved. Functionally, DM enhanced binding of 48–61
to I-Ak (Figure 2C). This effect was most pronounced hybridomas (e.g., 3A9) was undiminished after incuba-
tion for 14 days, indicating that the type A complexat limiting concentrations of I-Ak, suggesting saturable
kinetics of DM function and again consistent with previ- remained stable throughout this period (Figure 4A). By
comparison, the type B complex was short-lived, asous studies (Figure 2D). Finally, we tested whether DM
could protect class II molecules from inactivation in complexes formed in vitro lost the ability to stimulate
type B hybridomas with rapid, albeit varied, kineticsvitro. Preincubation of I-Ak at 37C resulted in rapid loss
of its ability to bind peptide (Figure 2E, left panel, (Figures 4B and 4C). Testing of additional type A and B
hybridomas yielded the same result (data not shown).DM/DM); however, this did not occur if DM was pres-
ent during the preincubation (Figure 2E, center panel, We therefore hypothesized that the DM-resistant and
DM-susceptible components might correlate with theDM/DM). Some degree of protection was observed
even when DM was added after preincubation, together type A and B conformers of the complex, respectively.
with peptide (Figure 2E, right panel,DM/DM). Collec-
tively, these observations indicate that our system accu- DM Eliminates the Type B Conformer by Direct
rately models DM function in vitro. Action on the MHC-Peptide Complex
To directly test this hypothesis, I-Ak/48–61 complexes
were formed in vitro in the presence or absence of DMDM Induces Biphasic Dissociation
of I-Ak/48–61 Complexes and tested for their ability to stimulate type A and B
hybridomas. In initial experiments, equivalent amountsWe subsequently examined the effect of DM on the
kinetics of dissociation of the I-Ak/48–61 complex (Figure of MHC-peptide complex were formed by 60 nM 48–61
with DM and 320 nM 48–61 without DM; these parame-3). In the absence of DM, I-Ak-peptide complexes disso-
ciated with monophasic kinetics (t1/2  1102 hr) (DM→ ters were used for all subsequent experiments (data not
shown). Complexes formed with and without DM wereDM). When DM was introduced (DM → DM at t 
0 hr), dissociation of the complex became biphasic, with equally capable of stimulating type A hybridomas, such
as 3A9 (Figure 5A). In contrast, type B hybridomas re-rapid decay (t1/2  15 hr; 27% of complexes) followed
by slow decay similar to that seen in the absence of DM sponded only to complexes formed in the absence of
DM (Figures 5B and 5C), indicating that DM prevents(t1/2  982 hr), indicating the presence of a mixture of
DM-susceptible and -resistant complexes. In support formation of the type B complex. These results could
conceivably be explained by two mechanisms. DMof this, when DM was present during formation of the
complex (DM → DM), dissociation was once again could act on empty or CLIP-associated class II during
synthesis or assembly, indirectly promoting formationmonophasic (t1/2  994 hr), indicating elimination of the
DM-susceptible component. Somewhat surprisingly, in- of one conformer versus the other, as suggested by the
studies of Pious and colleagues (Fling et al., 1994, 1997)troduction of DM following incubation without DM
DM Edits the Conformation of MHC-Peptide Complexes
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Figure 2. In Vitro System for Study of H2-DM Function
(A) Schematic diagram of constructs. See the Experimental Procedures for details.
(B) I-Ak and H2-DM form heterodimers in vitro which dissociate upon introduction of 48–61 peptide. Thrombin-treated I-Ak-CLIP was incubated
with an equimolar quantity of DM and excess 48–61 peptide for 3 hr at 37C. Complexes were then transferred to 96-well ELISA plates coated
with anti-DM monoclonal antibody (2E5A), incubated for 1 hr at room temperature, and washed. Complexes were detected with biotinylated
40F (anti-Ak) monoclonal antibody, followed by streptavidin-HRP and ABTS.
(C) DM enhances binding of 48–61 to I-Ak. Thrombin-treated Ak-CLIP (100 nM) was incubated with 125I-48–61 for 3 hr in the presence of varying
amounts of DM. MHC-peptide complexes were separated from free peptide by gel filtration, and binding was measured by quantitating the
amount of radioactivity associated with the complexes as a percentage of input peptide.
(D) Facilitation of binding by DM is most apparent at low concentrations of I-Ak. 125I-48–61 was incubated overnight with the indicated amounts
of Ak-CLIP in the presence or absence of an equimolar quantity of DM. Binding was assessed as in (C).
(E) DM protects I-Ak from inactivation. Left: Thrombin-treated I-Ak-CLIP (200 nM) was preincubated at 37C for the indicated lengths of time
(no preincubation, 2 hr, or 20 hr). 125I-48–61 was then added, and the incubation continued overnight, after which MHC-peptide complexes
were isolated by gel filtration, and binding was assessed as the percentage of input cpm associated with the complexes. Center: Same as
left panel, except that an equimolar quantity of DM (i.e., 200 nM) was present along with I-Ak during preincubation. Right: Same as left panel,
except that 200 nM DM was added simultaneously with radiolabeled peptide after the preincubation step.
and by others (Verreck et al., 2001). Alternatively, as bated the complexes briefly (2 hr) in the presence of
DM, then removed DM by cleavage with enterokinase,suggested by our kinetic data, DM could act via a novel
mechanism directly on the preformed MHC-peptide and tested presentation to type A and B hybridomas.
Introduction of DM did not affect the responses of typecomplex (Figure 3).
To distinguish these possibilities, complexes were A hybridomas but completely abolished the responses
of type B hybridomas, thus demonstrating that loss offormed in the absence of DM; we subsequently incu-
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traffics through the endosomal pathway to the lyso-
some-like class II loading vesicle; there, HEL is unfolded
and partially degraded by lysosomal hydrolases, gener-
ating peptides that complex with nascent class II mole-
cules. DM then edits the conformation of the complexes
so that only the most stable conformer, type A, emerges
from this compartment and is exported to the cell sur-
face (Figure 6A). In contrast, loading of exogenous pep-
tide occurs at the cell surface and in the early endosome
by exchange on class II molecules occupied by poorly
binding peptides. Due to the paucity of functional DM
in these compartments, the flexible type B conformer
forms in addition to the stable type A conformer (FigureFigure 3. H2-DM Induces Biphasic Dissociation of the I-Ak/48–61
6B). As a result, only type A T cells are primed by (andComplex
respond to) native protein, while immunization with ex-I-Ak-CLIP (200 nM) was incubated overnight with 125I-48–61 with or
ogenous peptide primes both type A and B T cells.without DM (200 nM). Complexes were isolated by gel filtration,
Our findings suggest a mechanism in which DM actsand the amount of bound radioactivity was quantitated. Excess
unlabeled peptide was then added; this time was defined as t  0. on a population of multiple conformers of the MHC-
For complexes formed without DM, DM was either added at t  0, peptide complex to eliminate flexible conformers and
t 70 hr, or not added as indicated. At various time points thereafter, promote formation of the conformer with minimum free
MHC-peptide complexes were isolated by gel filtration and the
energy. DM would thus function not only as an editoramount of peptide remaining bound was measured. The calculated
of the peptide repertoire, selecting high-affinity peptideshalf-lives and, where applicable, relative abundances of each com-
for binding to class II MHC, as is well established (Sloanponent (in parentheses) are: DM → DM, 1102 hr; DM → DM,
994 hr; DM → DM at t  0, 15 hr (27%) and 982 hr (73%); et al., 1995; Kropshofer et al., 1996; van Ham et al.,
DM → DM at t  70 hr, 6 hr (44%) and 1088 hr (56%). 1996; Weber et al., 1996; Vogt et al., 1996; Lovitch et
al., 2003b), but also as a conformational editor of MHC-
peptide complexes. While such a mechanism is sup-
type B reactivity occurred by direct action of DM on the ported by earlier observations of altered recognition by
preformed complex (Figures 5D–5F). class II-specific monoclonal antibodies in the absence
of DM (Fling et al., 1994, 1997; Verreck et al., 2001),
Discussion these findings were previously interpreted as resulting
from the action of DM during class II biosynthesis and
On the basis of these and other results, we explain the assembly; indeed, such observations would be ex-
presence of two sets of T cells against a single MHC- pected given that DM chaperones class II folding in the
peptide complex by conformational differences, in which endocytic pathway (Denzin et al., 1996; Kropshofer et
the DM molecule plays an editing role. We obtained al., 1997). In contrast, Mellins and colleagues proposed,
three major findings. First, the two conformers form in based on theoretical modeling of kinetic data, a mecha-
distinct intracellular compartments (a late endosomal/ nism by which DM acts as a conformational catalyst
lysosomal vesicle and the early endosome/cell surface), directly on MHC-peptide complexes (Zarutskie et al.,
indicating that different pathways of presentation give 2001; Belmares et al., 2003). Our findings support the
rise to each conformer. Second, this distinction is medi- latter model, providing direct evidence for such action
ated by DM, which could abolish the type B conformer at the level of T cell recognition. Whether DM-mediated
in vitro and was required for the compartmental segre- peptide and conformational editing share a common
gation observed ex vivo. Third, the action of DM in elimi- mechanism, as seems likely, is an intriguing subject for
nating the type B conformer could occur through direct further study.
action by DM on preformed MHC-peptide complexes. The physiologic importance of type B T cells should
not be underestimated. First, the abundance of type BWe propose a model in which intact protein (e.g., HEL)
Figure 4. The Type B Conformer Is Short-Lived Relative to the Type A Conformer
I-Ak-CLIP (200 nM) was incubated overnight with 320 nM unlabeled 48–61 peptide, and complexes were separated from free peptide by gel
filtration and incubated at 37C for the indicated lengths of time (0–14 days). Complexes were then coated onto 96-well plates, T hybridomas
added (105/well), and responses measured by CTLL assay.
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Figure 5. DM Abolishes the Type B Complex
(A–C) Selective formation of the type A complex in the presence of DM. I-Ak-CLIP (200 nM) was incubated with 60 nM 48–61 peptide in the
presence of DM (200 nM), or with 320 nM peptide in the absence of DM. Samples were neutralized, concentrated, treated with enterokinase
to remove bound DM, and coated onto 96-well plates; hybridomas were added and responses measured by CTLL assay as described.
(D–F) DM acts directly on the MHC-peptide complex to abolish the type B complex. I-Ak-CLIP (200 nM) was incubated with 320 nM 48–61
peptide in the absence of DM, and then incubated in the presence or absence of DM for an additional 2 hr. Responses of T hybridomas were
assayed as in (A)–(C).
T cells in the repertoire suggests that they represent a complexes from self-peptides in tissues could prime
self-reactive type B T cells, potentially triggering an au-specific mode of recognition of exogenous peptide;
aside from autoimmunity, this may be critical in antimi- toimmune response. Data exist to support several path-
ways by which type B T cells might be primed in vivo;crobial immunity, where peptides from processed mi-
crobes may reach the extracellular milieu. Second, the Strominger and colleagues have shown that ectoproteo-
lysis by immature dendritic cells generates peptidestype B phenomenon illustrates a critical pitfall of vacci-
nation strategies based on immunization with purified which are subsequently presented in trans (i.e., via the
exogenous pathway) to peptide-specific T cells (San-peptides; the immunizing peptide will preferentially in-
duce type B T cells that fail to recognize the peptide tambrogio et al., 1999), and neutrophils (Potter and Har-
ding, 2001) and serum proteases (Accapezzato et al.,processed from the native protein, likely resulting in an
ineffectual response to the pathogen against which the 1998) have been shown to have similar activity. Future
in vivo studies should shed light on these mechanisms.vaccine is directed. Finally, the generation of type B
Figure 6. Model for Formation of Distinct Conformers of an MHC-Peptide Complex
(A) Processing of intact protein results in peptide-MHC loading in late endosomal/lysosomal vesicles under the influence of DM, generating
only the type A conformer.
(B) Peptides can load by exchange in a process which does not involve DM, generating both the type A and B conformers. See text for details.
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Experimental Procedures the C terminus of the  chain. The resulting constructs were cloned
into the shuttle vector pBacpHp10 (Latek et al., 2000b) and trans-
fected into SF9 cells to generate recombinant baculoviruses. Pro-Mice
B10.BR (H-2k) mice were purchased from the Jackson Laboratory teins were expressed by infection of insect cells using standard
protocols and purified over Ni-NTA-agarose (Qiagen, Valencia, CA).(Bar Harbor, ME). DM/ (H-2k) mice were generated by targeted
disruption of the DM locus, as described previously, and subse-
quently backcrossed onto the B10.BR background (Koonce et al., Detection of DM-Ak Complexes
2003). All mice were maintained under specific pathogen-free condi- Formation of heterodimers of soluble I-Ak and H2-DM was deter-
tions at the Washington University School of Medicine. Peritoneal mined by sandwich ELISA. Nunc Maxisorp ELISA plates (Nunc,
macrophages were elicited from mice of either sex, between ages Roskilde, Denmark) were coated with the anti-H2-DM monoclonal
6 and 20 weeks. antibody 2E5A (BD Biosciences, San Diego, CA) at 10 g/ml in
carbonate buffer (pH 9.6, 1 g antibody/well) and incubated over-
night at 4C, then washed with PBS 0.05% Tween 20, and blockedPeptide Synthesis
in D5F for 1 hr. Separately, I-Ak, H2-DM, and/or peptide were com-HEL (48–63) peptide (DGSTDYGILQINSRWW) and related variants
bined, and samples were applied to the ELISA plate and incubatedwere synthesized using fluorenylmethoxycarbonyl (FMOC) chemis-
for 1 hr. After washing, 100 l of biotinylated 40F antibody (anti-I-try on a Symphony Multiplex peptide synthesizer (Protein Technolo-
Ak; Pierres et al., 1981) diluted 1:1000 (2 g/ml) was added andgies, Tucson, AZ), purified to homogeneity by C18 reverse phase
incubated at room temperature for 1 hr; the ELISA was then devel-HPLC, and verified by mass spectrometry prior to use in assays.
oped with ABTS  0.03% H2O2 and absorbance was read at 405125I-labeled peptide was prepared using the chloramine-T method
nm on a Model 550 microplate reader (Bio-Rad, Hercules, CA).(McConahey and Dixon, 1980).
MHC-Peptide Binding and Dissociation AssaysLiposome Preparation and Assays
To assess peptide binding to I-Ak, recombinant I-Ak-CLIP wasDioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylethano-
treated with thrombin (Novagen, Madison, WI) overnight at 4C, thenlamine (DOPE), and dioleoylphosphatidylserine (DOPS) were pur-
combined with varying amounts of DM and 125I-48–61 peptide inchased from Avanti Polar Lipids (Alabaster, AL) and dissolved in
binding buffer (25 mM HEPES, 25 mM MES, 150 mM NaCl [pH 5.5]),chloroform. Cholesteryl hemisuccinate (CHEMS) was purchased
and incubated at 37C for 3 hr or overnight. MHC-peptide complexesfrom Sigma (St. Louis, MO) and dissolved in methanol. All lipids
were separated from free peptide by gel filtration using Bio-Spin 6were stored under nitrogen at 20C.
columns (Bio-Rad), and incorporated radioactivity was measuredLiposomes were prepared essentially as described by Harding et
by 	-scintillation counting. To assess protection of I-Ak from inacti-al. (1991), with minor modifications. In brief, DOPC/DOPS or DOPE/
vation, thrombin-treated I-Ak-CLIP (200 nM) was preincubated atCHEMS were combined at a molar ratio of 4:1 (10 mol total lipid).
37C for varying lengths of time (0, 2, or 20 hr) in the presence orThe lipid mixture was dried under nitrogen, lyophilized to remove
absence of equimolar DM. 125I-48–61 peptide was then added; inresidual solvent, and reconstituted in 1 ml 0.2 PBS  0.2 mM
some cases, DM (200 nM) was also added at this stage. After over-EDTA containing 60–100 nmol peptide; a trace amount of 125I-labeled
night incubation at 37C, complexes were purified by gel filtration,peptide was added to measure incorporation. Liposomes were rehy-
and incorporated radioactivity was measured as described above.drated at 42C for 30 min, freeze-thawed five times in dry ice-ethanol,
Inactivation was thus read out as the loss of binding capacity dur-and passed 11 times through a Liposofast extruder (Avestin, Ottawa,
ing preincubation.Canada) with 200 nm pore size polycarbonate filter. Unencapsulated
To assess dissociation of peptide-I-Ak complexes, thrombin-peptide was removed by digestion with 0.2 mg/ml Pronase E (Roche,
treated I-Ak-CLIP (200 nM) was incubated overnight at 37C withBasel, Switzerland) for 2 hr at 37C and overnight dialysis against
125I-48–61 peptide in the presence or absence of 200 nM H2-DM.PBS  0.2 mM EDTA. Recovery of radiolabeled peptide was deter-
pH was neutralized and MHC-peptide complexes isolated by gelmined by 	-scintillation counting (Wallac, Turku, Finland); from this,
filtration, after which samples were readjusted to pH 5.5, and 150incorporation efficiency was determined (fraction of input cpm re-
mM NaCl and excess unlabeled peptide were added to preventcovered; generally 8%–10%), and the concentration of encapsu-
reassociation of labeled peptide. At various time points thereafter,lated peptide was calculated by dividing the total amount of encap-
aliquots were isolated, free peptide removed by gel filtration, andsulated peptide (input peptide multiplied by the incorporation
bound radioactivity measured. Kinetics of dissociation (monophasicefficiency) by the final volume after dialysis. Liposomes were used
versus biphasic) and half-lives were determined using Prism soft-immediately in assays or stored at 4C for no longer than 1 week.
ware (GraphPad, San Diego, CA).For presentation assays, peritoneal exudate cells were elicited by
intraperitoneal injection of B10.BR mice with 100 g concanavalin
A (Sigma) in pyrogen-free saline; mice were sacrificed 96 hr after T Hybridoma Assays Using In Vitro MHC-Peptide Complexes
injection, and cells were harvested by peritoneal lavage with Thrombin-treated I-Ak-CLIP (200 nM) was combined with 60 nM
DMEM  5% fetal calf serum. Dendritic cells were isolated from (with DM) or 320 nM (without DM) 48–61 peptide in the presence or
spleens of B10.BR mice by positive selection using anti-CD11c- absence of H2-DM (200 nM), and incubated overnight at 37C in
conjugated magnetic beads (Miltenyi Biotec, Gladbach, Germany). 150 mM NaCl (pH 5.5). Free peptide was then removed by buffer
105 cells/well were transferred to flat-bottom 96-well plates (Costar, exchange using a Centricon YM-30 concentrator (Millipore, San
Corning, NY) and adhered for 1 hr at 37C and 5% CO2. Liposomes Jose, CA). In some assays, complexes were subsequently incubated
diluted in DMEM  5% FCS were added, and cells were incubated at 37C and pH 5.5 for an additional period of time. Complexes were
for 2 hr at 37C, then fixed in 1% paraformaldehyde and 0.2 M lysine, then neutralized, concentrated, centrifuged for 10 min at 10,000 rpm
and washed extensively. Hybridoma (5  104/well) was added and to remove aggregates, and transferred to flat-bottom 96-well plates.
incubated for 18 hr, and supernatants were assayed for IL-2 content Complexes were adhered by incubation for 3–4 hr at 4C, then
by CTLL proliferation (2  104/well), with 3H-thymidine added for washed extensively. Hybridoma cells (1 105/well) were then added
the final 8 hr of a 24 hr culture. Incorporation was measured by and incubated overnight at 37C and 5% CO2, after which IL-2 pro-
-scintillation counting (Wallac). duction was assessed by CTLL assay. Elimination of the centrifuga-
tion step or precoating of plates with DM prior to application of Ak-
peptide complexes had no effect on results, indicating that centrifu-Generation of Soluble I-Ak and DM
gation did not alter the complexes and that DM and I-Ak did notVectors encoding the cDNA for the I-Ak-CLIP  and  chains (Latek
compete for adherence to the 96-well plate (data not shown).et al., 2000b) were modified by removal of the thrombin site on Ak
by PCR mutagenesis (CGC→GGC). Vectors encoding the cDNA for
the H2-DM  and 2 chains (Fremont et al., 1998b) were generously Acknowledgments
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